Norio Nakatsuji/X
Jun 20, 2026, 07:09
Norio Nakatsuji: LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
Norio Nakatsuji, Professor Emeritus at Kyoto University, Director General at Nakatsuji Foresight Foundation, Chief Advisor at Stem Cell and Device Lab, Inc. Bluesky, shared on X:
”LRP5 Inhibition Shows Promise for Safer Blood-Thinning Strategies
‘LRP5 inhibition reduced platelet activation and thrombosis with lower bleeding impact than current drugs.”’

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 17, 2026, 14:54Cindy Neunert: Beyond Platelet Counts – Addressing Fatigue and Whole-Person Care in ITP
-
Nov 17, 2026, 14:44Strengthening Haemophilia Diagnosis Through Hands-On Laboratory Training – IAHAD
-
Nov 17, 2026, 14:41Jens Helby: Long-Term Outcomes of Incidentally Detected Thrombocytopenia
-
Nov 17, 2026, 14:40Platelet Membrane Protrusions Beyond Their Role in Hemostasis – JTH
-
Nov 17, 2026, 14:10Wolfgang Miesbach: Aspirin vs Anticoagulants – Who Needs More Than Aspirin?
-
Nov 17, 2026, 14:08Chaza Alaji: Soluble Transferrin Receptor – A Key to Uncovering Hidden Iron Deficiency
-
Nov 17, 2026, 14:03Shadi Tabibian: Fibrinogen – From Molecular Structure to Clinical Decision Making
-
Nov 17, 2026, 13:54Gabrielle Sarlon: Breaking the Silence on Menstrual Bleeding During Anticoagulant Therapy
-
Nov 17, 2026, 13:47Ksenia Guznova Kats: Advanced Venous Stenting in May–Thurner Syndrome